Meta Pixel

News and Announcements

Unlocking Investor Confidence: The Value of 3rd Party IP Valuations

  • Published July 06, 2023 11:00PM UTC
  • Publisher Wholesale Investor
  • Categories Capital Raising Tips

When it comes to attracting investors, innovative companies understand the significance of having their intellectual property (IP) valued by third-party experts. However, not all entrepreneurs fully grasp the impact that these valuations can have on an investor’s decision-making process. In this enlightening video, we delve into the perspectives of investors regarding third-party IP valuations and shed light on the factors you need to consider to ensure that your valuation holds weight throughout your capital-raising endeavors.

During the introduction, you’ll gain a comprehensive overview of the importance of third-party IP valuations and their role in investor perception. We then dive deeper into the key factors that investors take into account when evaluating the credibility and potential of your IP valuation. Understanding these factors will enable you to present your IP valuation in a way that resonates with potential investors, enhancing your chances of securing funding.

YouTube player

Additionally, we emphasise the significance of knowing your target audience, as each investor may have unique preferences and priorities when it comes to IP valuations. We also explore the relevance of “discounted cash flow” in the investor’s assessment process and unveil what investors truly want to know about your IP assets.

By watching this video, you will gain valuable insights into how to leverage third-party IP valuations effectively to instill confidence in investors. Armed with this knowledge, you can strategically position your IP assets, strengthen your capital-raising efforts, and increase your chances of securing the funding your company deserves.

Don’t miss this opportunity to unlock the potential of third-party IP valuations and take your capital-raising journey to new heights.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now